Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Bell

Showing results (131-140 of 199) with videos related to

Pageof 20
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2011
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanomaTae-Ho Hwang, Anne Moon, James Burke, et al.
Science Translational Medicine|May 17, 2013
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humansMi Kyung Kim, Caroline J Breitbach, Anne Moon, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN productionTommy Alain, XueQing Lun, Yvan Martineau, et al.
Cancer Research|May 10, 2014
Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potencyAlexander Muik, Lawton J Stubbert, Roza Z Jahedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinomaNehad M Alajez, Joseph D Mocanu, Wei Shi, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Oncolytic Maraba virus MG1 mediates direct and natural killer cell-dependent lysis of Ewing sarcomaTyler Barr, Victoria A Jennings, Elizabeth A Roundhill, et al.
Oncoimmunology|December 8, 2018
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumorsJonathan G Pol, Sarah Lévesque, Samuel T Workenhe, et al.
Plos One|February 2, 2011
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitorsHeather MacTavish, Jean-Simon Diallo, Baocheng Huang, et al.
Molecular Therapy Oncolytics|August 21, 2019
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer TherapyAdrian Pelin, Johann Foloppe, Julia Petryk, et al.
Cancers|October 29, 2025
Oncolytic Maraba Virus MG1 Mediates Direct and Natural Killer Cell-Dependent Lysis of Ewing SarcomaTyler Barr, Victoria A Jennings, Elizabeth A Roundhill, et al.
Pageof 20

Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2011
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanomaTae-Ho Hwang, Anne Moon, James Burke, et al.
Science Translational Medicine|May 17, 2013
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humansMi Kyung Kim, Caroline J Breitbach, Anne Moon, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN productionTommy Alain, XueQing Lun, Yvan Martineau, et al.
Cancer Research|May 10, 2014
Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potencyAlexander Muik, Lawton J Stubbert, Roza Z Jahedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinomaNehad M Alajez, Joseph D Mocanu, Wei Shi, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Oncolytic Maraba virus MG1 mediates direct and natural killer cell-dependent lysis of Ewing sarcomaTyler Barr, Victoria A Jennings, Elizabeth A Roundhill, et al.
Oncoimmunology|December 8, 2018
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumorsJonathan G Pol, Sarah Lévesque, Samuel T Workenhe, et al.
Plos One|February 2, 2011
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitorsHeather MacTavish, Jean-Simon Diallo, Baocheng Huang, et al.
Molecular Therapy Oncolytics|August 21, 2019
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer TherapyAdrian Pelin, Johann Foloppe, Julia Petryk, et al.
Cancers|October 29, 2025
Oncolytic Maraba Virus MG1 Mediates Direct and Natural Killer Cell-Dependent Lysis of Ewing SarcomaTyler Barr, Victoria A Jennings, Elizabeth A Roundhill, et al.
Pageof 20